The review aims at comparing the learnings from SGLT‐2i CVOTs in T2DM to T1DM on a mechanistic basis and, to best current knowledge, elaborate why and when it could be particularly advantageous to consider SGLT‐2i use as an adjunct therapy to insulin in patients with T1DM, especially with respect to concomitant CVD and renal outcomes. The gene discussed is INS; the disease is type 2 diabetes mellitus.